Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location

Q: What is pan-immune-inflammation value (PIV) and why is it studied in colon cancer?

PIV is a systemic immune response marker. Research indicates it can predict prognosis in colon cancer, but its differences between left- and right-sided disease required further clarification.

Q: How was the study designed to evaluate PIV in left-sided and right-sided colon cancer?

A multicenter retrospective cohort included 1510 colon cancer patients (801 LCC and 709 RCC). The study used generalized lifting regression to assess PIV’s impact on DFS and applied Kaplan-Meier plus uni- and multivariate analyses for risk factors and correlations.

Q: What did the results show about PIV’s prognostic value by tumor location?

PIV was higher in RCC than in LCC. After propensity score matching, PIV differed no longer between groups; however, higher PIV predicted worse DFS in LCC, while no significant association was found in RCC.

Sep 21, 2026

Uploaded by Miles

Pan-immune-inflammation value (PIV) functions as a systemic immune response marker with prognostic relevance in colon cancer, yet differences between left-sided colon cancer (LCC) and right-sided colon cancer (RCC) remain insufficiently defined. This multicenter retrospective cohort study evaluated 1510 patients to determine PIV’s prognostic and clinical significance for disease-free survival (DFS). Generalized lifting regression, Kaplan-Meier, and uni-/multivariate analyses assessed risk factors and associations, including after propensity score matching.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Abstract

Background

Aim

Methods

Results

Conclusion

Introduction

Role of inflammation and PIV in colorectal cancer

| W | J | G | World Journal of
Gastroenterology | | --- | --- | --- | --- | Submit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2024 September 7; 30(33): 3823-3836 DOI: 10.3748/wjg.v30.i33.3823 ISSN 1007-9327 (print) ISSN 2219-2840 (online) ORIGINAL ARTICLE Retrospective Cohort Study Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location Qian-Yu Wang, Wen-Tao Zhong, Yi Xiao, Guo-Le Lin, Jun-Yang Lu, Lai Xu, Guan-Nan Zhang, Jun-Feng Du, Bin Wu Specialty type: Gastroenterology and hepatology Provenance and peer review: Unsolicited article; Externally peer reviewed. Peer-review model: Single blind Peer-review report’s classification Scientific Quality: Grade B, Grade B Novelty: Grade B, Grade B Creativity or Innovation: Grade B, Grade C Scientific Significance: Grade B, Grade B P-Reviewer: Bhattacharya S; Siena S Received: July 10, 2024 Revised: August 2, 2024 Accepted: August 19, 2024 Published online: September 7, 2024 Processing time: 53 Days and 16.1 Hours Qian-Yu Wang, Yi Xiao, Guo-Le Lin, Jun-Yang Lu, Lai Xu, Guan-Nan Zhang, Bin Wu, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China Wen-Tao Zhong, Jun-Feng Du, Medical Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China Co-corresponding authors: Jun-Feng Du and Bin Wu. Corresponding author: Bin Wu, MD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, [China.](China. wubin@pumch.cn)[ wubin@pumch.cn](China. wubin@pumch.cn) Abstract BACKGROUND A growing body of research indicates significant differences between left-sided colon cancers (LCC) and right-sided colon cancers (RCC) . Pan-immune-inflammation value (PIV) is a systemic immune response marker that can predict the prognosis of patients with colon cancer. However, the specific distinction between PIV of LCC and RCC remains unclear. AIM To investigate the prognostic and clinical significance of PIV in LCC and RCC patients. METHODS This multicenter retrospective cohort study included 1510 patients with colon cancer, comprising 801 with LCC and 709 with RCC. We used generalized lifting regression analysis to evaluate the relative impact of PIV on disease-free survival (DFS) in these patients. Kaplan-Meier analysis, as well as univariate and multivariate analyses, were used to examine the risk factors for DFS. The correlation between PIV and the clinical characteristics was statistically analyzed in these patients. RESULTS A total of 1510 patients {872 female patients (58%); median age 63 years [inter- WJG [https://www.wjgnet.com](https://www.wjgnet.com) 3823 September 7, 2024 Volume 30 Issue 33 Wang QY et al. PIV between in LCC and RCC quartile ranges (IQR): 54-71]; patients with LCC 801 (53%); median follow-up 44.17 months (IQR 29.67-62.32)} were identified. PIV was significantly higher in patients with RCC [median (IQR): 214.34 (121.78-386.72) vs 175.87 (111.92-286.84), P < 0.001] . After propensity score matching, no difference in PIV was observed between patients with LCC and RCC [median (IQR): 182.42 (111.88-297.65) vs 189.45 (109.44-316.02); P = 0.987] . PIV thresholds for DFS were 227.84 in LCC and 145.99 in RCC. High PIV (> 227.84) was associated with worse DFS in LCC [PIV-high: Adjusted hazard ratio (aHR) = 2.39; 95% confidence interval: 1.70-3.38; P < 0.001] but not in RCC (PIV-high: aHR = 0.72; 95% confidence interval: 0.48-1.08; P = 0.114) . CONCLUSION These findings suggest that PIV may predict recurrence in patients with LCC but not RCC, underscoring the importance of tumor locat

FAQs

What is pan-immune-inflammation value (PIV) and why is it studied in colon cancer?

PIV is a systemic immune response marker. Research indicates it can predict prognosis in colon cancer, but its differences between left- and right-sided disease required further clarification.

How was the study designed to evaluate PIV in left-sided and right-sided colon cancer?

A multicenter retrospective cohort included 1510 colon cancer patients (801 LCC and 709 RCC). The study used generalized lifting regression to assess PIV’s impact on DFS and applied Kaplan-Meier plus uni- and multivariate analyses for risk factors and correlations.

What did the results show about PIV’s prognostic value by tumor location?

PIV was higher in RCC than in LCC. After propensity score matching, PIV differed no longer between groups; however, higher PIV predicted worse DFS in LCC, while no significant association was found in RCC.

Sep 21, 2026

Uploaded by Miles